• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Turkey·Healthcare·ECILC.IS
Share

EIS Eczacibasi Ilac, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. Stocks

TRY 75.9Last Updated 10.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

TRY 1.11B

TRY 75.9
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a Turkish enterprise, operating predominantly in the health and real estate development sectors through its various subsidiaries. Its Health division is responsible for the production and distribution of pharmaceutical goods for both human and veterinary applications. Concurrently, the Real Estate Development segment is engaged in property creation and offers consultancy pertaining to land development and project oversight. This company, established in Istanbul, Turkey, in 1951, functions as a subsidiary of Eczacibasi Holding A.S.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, ove

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 02:42

Prosecutors from 12 U.S. states have filed a lawsuit against the Paramount-Warner Bros. Discovery deal

14.07.2026 01:22

SK Hynix Led the Decline Among Chipmakers; Oil Prices Suffered Their Sharpest One-Day Drop Since 2020

14.07.2026 00:44

Oil prices jumped by nearly 10%. The price of Brent crude exceeded $83 per barrel

14.07.2026 00:19

The top-performing stock in the S&P 500 has risen 600% this year. Evercore expects it to rise another 80%.

13.07.2026 23:47

Investors' bets on AI have bolstered the dollar. Why has this now become a risk for the currency?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026